Compare · ILMN vs PMD
ILMN vs PMD
Side-by-side comparison of Illumina Inc. (ILMN) and Psychemedics Corporation (PMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ILMN and PMD operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $29.37B, about 734.9x PMD ($40.0M).
- ILMN has hit the wire 3 times in the past 4 weeks while PMD has been quiet.
- ILMN has more recent analyst coverage (25 ratings vs 0 for PMD).
- Company
- Illumina Inc.
- Psychemedics Corporation
- Price
- $194.06-1.49%
- $2.68-3.60%
- Market cap
- $29.37B
- $40.0M
- 1M return
- +10.86%
- -
- 1Y return
- +76.55%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 3
- 0
- Recent ratings
- 25
- 0
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Psychemedics Corporation
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, amphetamines, opiates, synthetic cannabinoids, and benzodiazepines. Its testing results provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data that can show a pattern of individual drug use over a longer period-of-time. The company provides its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was founded in 1986 and is headquartered in Acton, Massachusetts.
Latest ILMN
- Illumina expands Billion Cell Atlas program with new AI drug developers
- Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
- Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
- Director Meister Keith A. was granted 142 shares, increasing direct ownership by 2% to 6,780 units (SEC Form 4)
- Director Ullem Scott B. was granted 167 shares, increasing direct ownership by 2% to 11,030 units (SEC Form 4)
- Bernstein resumed coverage on Illumina with a new price target
- Chief Legal Officer Davies Scott M sold $110,700 worth of shares (615 units at $180.00), decreasing direct ownership by 3% to 20,953 units (SEC Form 4)
- Director Skovronsky Daniel was granted 1,674 shares (SEC Form 4)
- SEC Form 3 filed by new insider Skovronsky Daniel
- Illumina Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Latest PMD
- Psychemedics Releases 2026 Education Insights Report
- Psychemedics Releases 2026 Workforce Insights Report
- Psychemedics Releases 2025 Workforce Insights Report
- Psychemedics Launches Groundbreaking Quartile Reporting for Enhanced Drug Testing Insights
- SEC Form 15-12G filed by Psychemedics Corporation
- Large owner Powell Anderson Capital Partners Llc bought $305,439 worth of shares (159,700 units at $1.91) (SEC Form 4)
- SEC Form 25 filed by Psychemedics Corporation
- Large owner Powell Anderson Capital Partners Llc bought $231,849 worth of shares (86,991 units at $2.67) (SEC Form 4)
- Amendment: SEC Form SC 13D/A filed by Psychemedics Corporation
- Director Kamin Peter sold $753,664 worth of shares (320,708 units at $2.35) (SEC Form 4)